Sitemap
- Travecta Therapeutics Appoints Douglas C. Hicks as Chief Business Officer
- SPRIM and Tikehau Capital Join Forces with New Singapore-based Life Sciences VC Fund
- Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta
- Duke-NUS Commercializes Discovery to Deliver Therapeutics Across Blood Brain Barrier
- Scientific Study Shows Milk with Only the A2 Beta Casein Protein Type Reduced Acute Gastrointestinal Symptoms in Milk Sensitive Participants
- Evid Science Receives Seed Capital to Advance Clinical AI Platform
- 3 Ways Mobile Clinical Trials Help Clinical Researchers Improve Diversity
- Fighting Antibiotic Associated Diarrhea
- Solving the Blood‑Brain Barrier Challenge
- ObvioHealth’s Milo Demonstrates How Digital Technology Improves Patient Experience, Compliance and Data Capture Using ClaimIt.
- Startups Aim to Fix ‘Broken’ Clinical Trials System
- RegAsk, a Healthcare RegTech Startup, Secures Venture Capital Funding in a Seed Round to Pursue Growth
- TKS 1 Investor Day 2019 in Singapore: Post Event Highlights
- Objective GI Funding Announcement
- Fibronostics Corporate Update
- SPRIM’s Quarterly Ventures Day Meeting in New York
- Video: Celebrating 15 Years with Unilever
- Bring Your Own Device in Clinical Research: The Four C’s
- 4 Things You Should Know Before Marketing CBD Products
- AC Health Announces Investment in Fibronostics
- SPRIM joins in support of International NASH Day
- Combating a Tainted Market: 3 Ways to Substantiate a Dietary Supplement Product
- RegTech: Easing the Burden of Compliance for FMCG
- Path-to-Market: How Regulatory Technology Can Help Companies Expand to Asia
- Clinical Trial Recruitment: Old Habits Die Hard
- Three Channels for Educating and Influencing Consumers in the Dietary Supplement Marketplace
- Recruiting a Diverse Subject Population
- The Growing Need for Medical Devices and the RegTech Solutions to Complex Regulations
- How SPRIM’s Practice Areas & Sister Companies Work Together to Build the Future of Health
- Digital vs. Traditional Clinical Trials: Examining the Differences
- Poster: Achieving Diversity in Clinical Trials
- U.S. Recycling Stream in Shambles: How CPG Companies can Change the Game
- Disruptive Healthcare Trends: 5 Innovations to Look for in 2020
- Real World Data and Evidence Revolutionize Clinical Research
- Ventures Day Singapore 2020: Post-event highlights
- Coronavirus Outbreak: Medical Staff Vulnerable, Telemedicine the Solution?
- ObvioHealth Launches Virtual COVID-19 Symptoms & Immune Response Registry
- Obvio-19 – Interview with CheddarTv
- Travecta Therapeutics Secures $15 Million in Financing
- ObvioHealth Secures $17 Million in Latest Investment Round
- SPRIM Partners with Health Catalyst to Analyze COVID-19 Impact on NASH and NAFLD
- Travecta Therapeutics Announces it has Closed its Oversubscribed Series A Round at $27 Million
- ObvioHealth and Hôpital Paris Saint-Joseph Announce Partnership to Track COVID-19 in Oncology Patients
- The Critical Need for Virtual COVID-19 Clinical Trials and Patient Training
- Fibronostics Appoints Dr. Stephen A. Harrison to its Board of Advisors
- Fibronostics Raises $8 Million in Series A Financing
- Leveraging Next-Gen Tools in Rare Disease Research
- Consumer Response to Nutrition during COVID-19 in Brazil
- AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies
- SPRIM Global Investments names Susan Dallabrida as Chief Executive Officer of SPRIM Consultancy
- Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer
- ObvioHealth Introduces ObvioGo™, a Next-Generation DCT Platform and Mobile Application Delivering Stronger Evidence
- Mi-Helper, Inc. (pronounced my-helper) announces initial $4M close from lead investors SPRIM Global, TEDCO and CoolTech in their $7M Series A Preferred financing.
- STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
- Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
- Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
- ObvioHealth to Conduct a Pioneering Decentralized Clinical Trial on The Mi-Helper Device for Treatment of Migraine
- STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
- 1nHealth Launches Site Advisory Board to Prioritize Site Voice
- AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates
- Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
- ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers
- SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd.
- Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight
- Spexis provides business update and announces financial results for the first half of 2023
- Fibronostics Announces Partnership with Stone Diagnostics
- ObvioHealth Strengthens Leadership Team with Key Industry Appointments
- RegASK Welcomes New Chief Product & Technology Officer
- Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
- Stalicla Secures $17.4 Million in Series B Financing
- Forbes Australia recognizes Prota Therapeutics for making waves in Australia’s startup scene at the moment
- ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally
- SPRIM PRO Announces a Novel and Validated Approach for Monitoring Infant Growth from Home in Clinical Trials, Reducing Burdens on Caregivers and Clinical Sites
- PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024
- Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year – Europe”
- Cilcare completes a €40M series A
- RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases
- ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation
- PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD
- Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform
- Four Critical Steps to Consider Prior to Going Global
- 5 Big Product Development Mistakes
- ObvioHealth Announces Mobile Application
- ObvioHealth Raises $3 Million in Series A Funding
- The Forgotten Piece to the Adherence Puzzle
- The Role of E-commerce in Product Innovation
- This is why your patient engagement dollars are wasted.
- Vanteres: New Study Reveals the Importance of Active-DHA in the Developing Brain
- When It’s Time to Fire Your Agency